Roche's SMA drug trial win bolsters $2 billion sales prospects

Roche's spinal muscular atrophy (SMA) drug risdiplam hit another clinical trial target, the Swiss drugmaker said on Thursday, which analysts said bolsters its prospects of reaching $2 billion in annual sales.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news